Edgewise Therapeutics, Inc. (EWTX) Revenue History
Annual and quarterly revenue from 2019 to present
EWTX Revenue Over Time (2019–2025)
EWTX Revenue Growth History
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
EWTX Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 22, 2026, Edgewise Therapeutics, Inc. (EWTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
EWTX's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including ACAD (+9.9% YoY), KYMR (-12.6% YoY), and ARQT (+95.3% YoY). Compare EWTX vs ACAD →
EWTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EWTXCurrent | $0 | - | - | - | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARQT | $376M | +95.3% | - | -3.3% |
EWTX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-2,266,000 | - | $-191,406,000 | - |
| 2024 | $0 | - | $0 | - | $-158,832,000 | - |
| 2023 | $0 | - | $0 | - | $-114,357,000 | - |
| 2022 | $0 | - | $0 | - | $-71,658,000 | - |
| 2021 | $0 | - | $0 | - | $-43,215,000 | - |
| 2020 | $0 | - | $-185,000 | - | $-17,192,000 | - |
| 2019 | $0 | - | $-123,000 | - | $-9,924,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EWTX — Frequently Asked Questions
Quick answers to the most common questions about buying EWTX stock.
Is EWTX's revenue growth accelerating or slowing?
EWTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is EWTX's revenue history from 2019 to 2026?
Edgewise Therapeutics, Inc. (EWTX) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is EWTX's long-term revenue growth rate (CAGR)?
Edgewise Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for EWTX.
Why does EWTX's quarterly revenue fluctuate?
EWTX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Edgewise Therapeutics, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is EWTX's revenue distributed by segment?
EWTX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does EWTX's revenue compare to industry peers?
Edgewise Therapeutics, Inc. (EWTX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.